Seurat Therapeutics, Inc.

2:15 PM - 2:30 PM, Tuesday, June 4,2019 ・ SuS - Hall E, Booth 3971, Level 200
Therapeutics company developing a nasal spray to alleviate and prevent future migraines. This treatment addresses the cause of migraines, as opposed to only symptom management, by utilizing a native biological protein recreated in a laboratory that prevents the onset of migraines, repairs damage brain cells, and reduces brain disease. It is predicted that this therapy could be applied as a treatment for other neurodegenerative diseases, such as Alzheimer's, due to its neurogenerative properties.
co-founder, President & CEO
Seurat Therapeutics, Inc.